一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括Apatinib；Dalpiciclib；Fulvestrant/AI，当前状态为研究进行中，已停止招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Apatinib；Dalpiciclib；Fulvestrant/AI · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Breast cancer institute of Fudan University Cancer Hospital · 上海
公开的入选条件
- * Females ≥18 years and ≤ 75 years old;
- * Histologically confirmed HR + / HER2- invasive breast cancer (specific definition: immunohistochemical detection of ER\> 10% tumor cell positive is defined as ER positive, PR\> 10% tumor cell positive is defined as PR positive, ER and / or PR Positive is def
- * Subtype of similarity network fusion-4 (SNF-4) confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan University Affiliated Cancer Hospital • Locally advanced breast cancer (incapable of radical local treatment) or recurrent me
- * Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1); or unmeasurable lytic or mixed (osteolytic + osteoblastic) bone lesions in the absence of measurable lesions;
- * Has adequate bone marrow function: absolute neutrophil count \> 1.5x10ˆ9 /L; platelet count \> 75x10ˆ9 /L, hemoglobin \> 9g/dL;
- * Patients had received no previous chemotherapy or targeted therapy for metastatic disease
- \- Page 3 of 4 \[DRAFT\]
- * Has adequate liver function and kidney function: serum creatinine
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05759572；登记信息更新于 2026-09-16。